An interventional cardiologist, Dr. Gupta is a renowned expert in the diagnosis and treatment of structural heart disease. His primary focus is on the treatment of severe aortic stenosis in patients who are eligible for transcatheter aortic valve replacement (TAVR).
A pioneer in the field of interventional cardiology, he was an early leader in the performance of TAVR. He has led several groundbreaking studies, including those seeking new indications for TAVR.
Dr. Gupta is clinical co-director for the division of cardiovascular medicine at University of Maryland School of Medicine. He is focused on developing a division that trains cardiologists dedicated to clinical care, education and research.
Board Certification and Education
Medical School:
University of Maryland School of Medicine, 1998
Residency:
Albert Einstein College of Medicine of Yeshiva University, 2001
Fellowship:
Weill Cornell Medical College - Cardiology, 2003
Temple University Hospital - Cardiology, 2006
New York-Presbyterian University Hospital of Columbia and Cornell - Interventional Cardiology, 2008
Certification:
American Board of Internal Medicine - Interventional Cardiology, 2007
American Board of Internal Medicine - Cardiovascular Disease, 2006
Hospital Affiliations
UM Capital Region Health
UM Shore Regional Health - Dorchester/Easton
University of Maryland Medical Center Midtown Campus
UM Baltimore Washington Medical Center
UM Upper Chesapeake Health
UM St. Joseph Medical Center
University of Maryland Medical Center
Research and Publications
A focus of Dr. Gupta's research includes evaluating new therapies for the treatment of cardiovascular disease. He was the site principal investigator for the PARTNER 2 trial as well as the Galileo, Early TAVR and Medtronic Low-Risk randomized TAVR trials.
Dr. Gupta is the principal investigator of the ALIGN-AR trial assessing TAVR for patients with severe aortic regurgitation. In addition, he is involved in renal denervation studies, including the SYMPLICITY-HTN3 and Reduce HTN: Reinforce trials. He is the site principal investigator for the OCEAN (a) trial, assessing a siRNA to reduce the pro-atherosclerotic Lipoprotein(a).
Ratings and Reviews
The star rating is an average of responses to our patient satisfaction survey. Patients measure their experience with our providers on a scale of 1 to 5 stars, 1 being “Very Poor” and 5 being “Very Good.” Learn more about the patient satisfaction survey.
